• Investors
  • News
  • Subscribe
Hit enter to search or ESC to close
Cardax, Inc. | CDXI
  • About Us
    • Corporate Overview
    • Corporate Presentation
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Lead Scientific Team
    • Company History
  • Astaxanthin
    • Overview
      • Astaxanthin Overview
      • History and Background
      • Safety
      • Mechanism of Action
      • Synthetic vs. Natural Astaxanthin
    • Research in Key Addressable Markets
      • Cardiovascular Disease
      • Metabolic Disease
      • Liver Disease
      • Arthritis
      • Aging
      • Coronavirus Disease 2019 (COVID-19)
    • Scientific Literature
  • Programs
    • Product Platform
    • Commercialization Strategy
    • CDX-101
    • CDX-301
    • ZanthoSyn®
    • CHASE Clinical Trial
    • Intellectual Property
  • Newsroom
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact Us
Cardax, Inc. | CDXI

Press Releases

Investor Relations
Investors
  • Overview
  • News / Events
    • Press Releases
    • Media Coverage
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Profile
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

Cardax Announces Effectiveness of Registration Statement and Commencement of Warrant Exchange Offer

Jun 22, 2018

Cardax Engages Industry Veteran Fred Sancilio, Ph.D., to Launch Orphan Drug Development Program

Jun 13, 2018

Cardax Adds Makarand Jawadekar, Ph.D., and Elona Kogan to its Board of Directors

Jun 1, 2018

Cardax Reports Q1 2018 Results

May 9, 2018

Cardax Announces Warrant Exchange Offer

May 2, 2018

Cardax Reports 2017 Results

Mar 27, 2018

Cardax Inks Deal to Distribute ZanthoSyn® in China

Feb 17, 2018

Cardax's ZanthoSyn® is No. 1 Seller at GNC Hawaii Stores

Feb 17, 2018

Cardax Hires Gilbert Shin as VP, Retail Sales and Marketing

Dec 7, 2017

ZanthoSyn® from Cardax Now Available at 3,000+ GNC Corporate Stores in the U.S.

Dec 7, 2017
RSS
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8

    News / Events

    • Press Releases
    • Media Coverage
    • IR Calendar
    • Presentations
    • Email Alerts
    Subscribe to Receive Updates by E-Mail Cardax News Alerts

    Recent News

    • Cardax Reports Q3 2020 ResultsNovember 13, 2020
    • Cardax Reports Q2 2020 ResultsAugust 14, 2020

    © 2021 Cardax, Inc. | Disclaimer and Terms of Use

    • About Us
      • Corporate Overview
      • Corporate Presentation
      • Management Team
      • Board of Directors
      • Scientific Advisory Board
      • Lead Scientific Team
      • Company History
    • Astaxanthin
      • Overview
        • Astaxanthin Overview
        • History and Background
        • Safety
        • Mechanism of Action
        • Synthetic vs. Natural Astaxanthin
      • Research in Key Addressable Markets
      • Scientific Literature
    • Programs
      • Product Platform
      • Commercialization Strategy
      • CDX-101
      • CDX-301
      • ZanthoSyn®
      • CHASE Clinical Trial
      • Intellectual Property
    • Newsroom
    • Investors
      • Investor Overview
      • News / Events
      • Company Information
      • Financial Information
      • Stock Information
      • SEC Filings
      • Corporate Governance
    • Contact Us
    • Investors
    • News
    • Subscribe